Muscle Invasive Bladder Cancer Market size is poised to reach USD 48 billion by the end of 2036, growing at a CAGR of 10% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of muscle invasive bladder cancer was over USD 21 billion. The rising personalized medicine and biomarker development is one of the main growth drivers expanding the market. A transformative and yet underutilized growth driver in the market is the integration of personalized medicine and the development of specific biomarkers. According to a study, the use of personalized medicine guided by biomarkers has shown a 30% improvement in progression-free survival in patients who received personalized treatments compared to those who underwent conventional treatments.
The future outlook for the MIBC market is positive, with the market expected to continue to grow in the coming years. This growth will be driven by the rising incidence of MIBC, the increasing prevalence of risk factors, and the development of new and more effective treatments. Muscle-invasive bladder cancer (MIBC) is a type of bladder cancer that has invaded the muscularis propria, the middle layer of the bladder wall. MIBC is more aggressive than non-muscle-invasive bladder cancer (NMIBC) and is more likely to spread to other parts of the body.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
~10% |
|
Base Year Market Size (2023) |
~ USD 21 Billion |
|
Forecast Year Market Size (2036) |
~ USD 48 Billion |
|
Regional Scope |
|
Type (Surgical Treatment, Non-Surgical Treatment)
The surgical treatment segment in the muscle invasive bladder cancer market is estimated to gain the largest revenue share of 61% in the year 2036. Compelling growth driver for surgical treatments in the MIBC market is the potential for cure. Radical cystectomy, in particular, offers a chance for certain patients to achieve long-term disease-free survival. While not all MIBC cases are curable, a subset of patients benefits from this aggressive surgical approach. A study published in "The Lancet" Oncology revealed that a subset of MIBC patients who underwent radical cystectomy experienced long-term disease-free survival, suggesting the potential for cure. Surgical interventions have the potential to eliminate cancerous tissue entirely, especially in cases where the cancer is confined to the bladder. Patients who achieve complete remission after surgery may experience long-term disease control and a potential cure.
End User (Hospitals, Patients, Pharmaceuticals)
Muscle invasive bladder cancer market from the hospitals segment is expected to garner a significant share in the year 2036. One significant growth driver for the hospitals segment in the MIBC market is the establishment of multidisciplinary care teams. MIBC is a complex disease that often requires a multifaceted approach to diagnosis and treatment. Multidisciplinary care teams consist of various specialists, including urologists, medical oncologists, radiation oncologists, pathologists, radiologists, and nurses, who collaborate to provide comprehensive care for MIBC patients. A study published in the "Journal of Clinical Oncology" found that multidisciplinary care teams, involving urologists, medical oncologists, and radiation oncologists, are associated with improved survival outcomes in MIBC patients.
Our in-depth analysis of the global market includes the following segments:
|
Type |
|
|
End User |
|
APAC Market Forecast
The muscle invasive bladder cancer market in the Asia Pacific region is projected to hold the largest revenue share of 40% by the end of 2036. Advances in medical technology are a significant growth driver in the MIBC market in the Asia Pacific region. The region has witnessed the adoption of state-of-the-art medical technologies, including advanced imaging techniques, diagnostic tools, and treatment modalities. The Asia Pacific region has embraced technological advancements in the field of medical imaging, including the use of positron emission tomography-computed tomography (PET-CT) for precise staging of MIBC. In particular, the use of positron emission tomography-computed tomography (PET-CT) has gained prominence in the precise staging of MIBC. This imaging modality allows for the comprehensive assessment of the extent of the disease, facilitating treatment planning and decision-making.
North American Market Statistics
The muscle invasive bladder cancer market in the North America region is projected to hold the second largest share during the forecast period. One of the prominent growth drivers in the MIBC market in North America is the aging population. The United States and Canada, in particular, are witnessing a demographic shift with a growing elderly population. In the United States, the aging population is growing rapidly, with the number of individuals aged 65 and older projected to reach 88 million by 2050. Muscle-invasive bladder cancer is more common in older individuals. The aging process can lead to cellular changes in the bladder, making it more susceptible to carcinogenic factors. Therefore, the rising elderly population directly contributes to the increased incidence of MIBC in North America.
Author Credits: Radhika Gupta, Shivam Bhutani
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?